ER4.F Stock Analysis
ER
Uncovered
Emergent BioSolutions Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,500 full-time employees. The company went IPO on 2006-11-15. Its segments include Products Segment and Services Segment. The Products Segment includes the government-medical countermeasures (MCM) business, which focuses on procurement of MCM products and procured product candidates by domestic and international government customers. The company sells MCM products and procures product candidates to domestic and international non-government organizations and to governments outside of the United States. The company also includes the commercial business, which focuses on sales of NARCAN (naloxone HCI) Nasal Spray and its travelers' vaccines. The Services Segment consists of contract development and manufacturing (CDMO) services, which includes development services (process and analytical development), drug substance manufacturing and drug product manufacturing (fill/finish).